BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS:Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS:Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
RCT Entities:
BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialogangliosideGD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS:Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
Authors: J D Frost; J A Hank; G H Reaman; S Frierdich; R C Seeger; J Gan; P M Anderson; L J Ettinger; M S Cairo; B R Blazar; M D Krailo; K K Matthay; R A Reisfeld; P M Sondel Journal: Cancer Date: 1997-07-15 Impact factor: 6.860
Authors: K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds Journal: N Engl J Med Date: 1999-10-14 Impact factor: 91.245
Authors: A L Yu; M M Uttenreuther-Fischer; C S Huang; C C Tsui; S D Gillies; R A Reisfeld; F H Kung Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: R Handgretinger; K Anderson; P Lang; R Dopfer; T Klingebiel; M Schrappe; P Reuland; S D Gillies; R A Reisfeld; D Neithammer Journal: Eur J Cancer Date: 1995 Impact factor: 9.162
Authors: Kaci L Osenga; Jacquelyn A Hank; Mark R Albertini; Jacek Gan; Adam G Sternberg; Jens Eickhoff; Robert C Seeger; Katherine K Matthay; C Patrick Reynolds; Clare Twist; Mark Krailo; Peter C Adamson; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: M R Albertini; J A Hank; J H Schiller; M Khorsand; A A Borchert; J Gan; R Bechhofer; B Storer; R A Reisfeld; P M Sondel Journal: Clin Cancer Res Date: 1997-08 Impact factor: 12.531
Authors: Hua Fang; Theresa M Harned; Ondrej Kalous; Vanessa Maldonado; Yves A DeClerck; C Patrick Reynolds Journal: Clin Cancer Res Date: 2011-09-20 Impact factor: 12.531
Authors: E L Carpenter; E A Haglund; E M Mace; D Deng; D Martinez; A C Wood; A K Chow; D A Weiser; L T Belcastro; C Winter; S C Bresler; M Vigny; P Mazot; S Asgharzadeh; R C Seeger; H Zhao; R Guo; J G Christensen; J S Orange; B R Pawel; M A Lemmon; Y P Mossé Journal: Oncogene Date: 2012-01-23 Impact factor: 9.867
Authors: Jorge Delgado; Diego Jaramillo; Nancy A Chauvin; Michelle Guo; Mackenzie S Stratton; Hannah E Sweeney; Christian A Barrera; Sogol Mostoufi-Moab Journal: Pediatr Radiol Date: 2019-05-04
Authors: Brian H Kushner; Irene Y Cheung; Shakeel Modak; Kim Kramer; Govind Ragupathi; Nai-Kong V Cheung Journal: Clin Cancer Res Date: 2014-02-11 Impact factor: 12.531
Authors: Stephan A Grupp; Eline Luning Prak; Jean Boyer; Kenyetta R McDonald; Suzanne Shusterman; Edward Thompson; Colleen Callahan; Abbas F Jawad; Bruce L Levine; Carl H June; Kathleen E Sullivan Journal: Clin Cancer Res Date: 2012-10-23 Impact factor: 12.531
Authors: Hung C Tran; Zesheng Wan; Michael A Sheard; Jianping Sun; Jeremy R Jackson; Jemily Malvar; Yibing Xu; Larry Wang; Richard Sposto; Eugene S Kim; Shahab Asgharzadeh; Robert C Seeger Journal: Clin Cancer Res Date: 2016-10-10 Impact factor: 12.531